Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2003 / N 4

Влияние статинов на нелипидные маркеры ишемической болезни сердца: С-реактивный белок и фибриноген
А.В. Сусеков

Список литературы
1) Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2) Shepherd J, Cobbe SM, Isles CG, Lorimer AR, Macfariane PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
3) Sacks FN, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N. Engl. J. Med. 1996; 335: 1001-1009.
4) The long-term prevention with pravastatin in ischemic disease (LIPID) Study Group .Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349-1357.
5) Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beer PA et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels . JAMA 1998; 279:1615-1622.
6) Shepherd J, Blauw GJ, Murphy MB, Bollen E et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
7) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in moderately hypercholesterolemic, hypertensive patients randomized to Pravastatin vs Usual Care. The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288 (23):2898-3007.
8) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo- controlled trial. Lancet 2002; 360:7-22.
9) Balk EM, Lau J, Goudas LC, Jrdan HS et al. Effect o satins on nonlipid serum markers associated with cardiovascular disease. Ann. Intern Med. 2003; 139(8):670.
10) Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med. 1999;340:115-26.
11) Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels : the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
12) Karas RH. Acute Coronary Syndromes: Molecular Basis of cardiac Risk Factors. J. Thromb. Thrombolysis. 1997; 4:167-175.
13) Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
14) Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003;35(6):398-403.
15) Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J. 2003;24:225-48.
16) Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003 Aug;21(3):315-25.
17) Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003 Aug 21;92(4B):17K-22K.
18) Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-15.
19) van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166:129-35.
20) Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am. Coll Cardiol. 1999;33:1294-304.
21) Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877-83.
22) Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-5.
23) Kalela A, Laaksonen R, Lehtimäki T, Koivu TA, Höyhtyä M, Janatuinen T, et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol. 2001;88:173-5.
24) Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GY. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol. 2001; 88:7-8.
25) Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol. 2002;90:942-6.
26) Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447-52.
27) Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high- sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213-7.
28) Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001;85:47-51
29) Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-5
30) Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-60
31) van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 2002;165:361-6.
32) Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002;251:338-47.
33) van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs- CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 2002;165:361-6.
34) Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis. 2002;162:245-51.
35) Mohrschladt MF, de Maat MP, Westendorp RG, Smelt AH. C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy. Atherosclerosis. 2001;157:491-4.
36) Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002;23:794-9.
37) Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J. 2003;145:8-8.
38) Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
39) Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci. 1996 Jun;32(6):364-70.
40) Ernst E, Koenig W. Fibrinogen and cardiovascular risk. Vasc. Med. 1997;2:115-25.
41) Betteridge DJ. Ciprofibrate – a profile. Postgraduate Med. J. 1993;69 (Suppl.1):S42-S49.
42) de Maat MPM., Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb. Haemost 1997;77:75-79.
43) Farnier M., Bonnefous F, Debbas N et al. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type I I a and II b hyperlipideamia. Arch Intern Med. 1994;194:441-9.
44) Durrington DN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S et al. Effects of two different derivates on lipoproteins, cholesterol ester transfer , fibrinogen, plasminogen activator inhibitor and paroxonase activity in type II b hyperlipideamia. Atherosclerosis 1998;138:217-225.
45) Kock M, Princen HM, Kooistra T., Fibrate-modulated expression of fibrinogen , plasminogen activator inhibitor –1 and apolipoprotein A-! in cultured cynomolgus monkey hepatocytes: role of the peroxisome proliferator-activator receptor alpha. Thromb. Haemost. 1998;80:942-948.
46) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19): 2486-2497.
47) Dangas G, Badimon JJ, Smith DA et al. Pravastatin therapy in hyperlipidaemia: efects on trombus formation and the systemic hemostatic profile.J. Am. Coll. Card. 1999;33:1294-304.
48) McDowell IF, Smye M, Trinic T, Shortt JA et al. Simvastatin in severe hypercholesterolaemia: a placebo-controlled trial. Br. J. Pharmacology 1991;31:340-3.
49) Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur. Heart J. 1997;18:235-41.
50) Jacobs H Jacobs H, Van de Werf F, Lesaffre E, De Geest H, Collen D. A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters Acta Clin Belg. 1992;47:82-9.
51) Dupuis J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-33 .
52) Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. [PMID: 7671358] Circulation. 1995;92:1758-64 .
53) Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani GD. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Current Therapeutic Research. 1994;55:1335-44.
54) Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thromb Haemost. 2000;84:553-8.
55) John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. [PMID: 9697820] Circulation. 1998;98:211-6.
56) Haak E, Abletshauser C, Weber S, Goedicke C, Martin N, Hermanns N, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia Atherosclerosis. 2001;155:395-401.
57) Tan KC, Janus ED, Lam KS. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. Am J Cardiol. 1999;84:934-7.
58) Farrer M, Winocour PH, Evans K, Neil HA, Laker MF, Kesteven P, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract. 1994;23:111-9.
59) Wierzbicki AS, Lumb PJ, Chick G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. International Journal of Clinical Practice. 1999; 53(8): 609-611.

60) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.Circulation. 2000 Jul 4;102(1):21-7.

61) Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation. 1999;100(5):475-82.
62) Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. : JAMA. 2001 Apr 4;285(13):1711-8.
63) SoRelle R.Cardiovascular news. FLORIDA.Circulation. 2000 Dec 19;102(25):E9050-1.
64) Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Veldhuisen DJ; FLuvastatin On Risk Diminishment after Acute myocardial infarction study group.Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J. 2002 Dec;23(24):1931-7.
65) Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]